|[April 01, 2014]
SAGE Therapeutics Appoints Howard H. Pien to the Company's Board of Directors
CAMBRIDGE, Mass. --(Business Wire)--
SAGE Therapeutics, a biopharmaceutical company developing novel
medicines to treat life-threatening, rare central nervous system (CNS)
disorders, today announced the appointment of Howard H. Pien to the
company's board of directors.
"Howard is a seasoned industry leader with deep biopharmaceutical
expertise, especially in guiding companies as they expand and evolve
from research and development to clinical stage," said Jeff Jonas, M.D.,
chief executive officer of SAGE Therapeutics. "We are pleased to welcome
him to the SAGE team and believe he will be an invaluable asset as we
advance our clinical and preclinical programs in orphan and acute CNS
disorders, including status epilepticus."
Mr. Pien has been a chairman of Vanda Pharmaceuticals, a CNS development
company, and lead independent director of ViroPharma, Inc., an orphan
disease company. Additionally, he currently sits on the board of
directors of Immunogen, Inc. and Juno Therapeutics, and is also an
advisor to the life sciences practice of Warburg Pincus (News - Alert). He is the
former chief exective officer and chairman of Medarex, Inc., where he
served for two years prior to the company's acquisition by Bristol-Myers
Squibb Company in 2009. While at Medarex, Mr. Pien shepherded the
evolution of the company from a technology platform enterprise to a
promising developer of oncology and immunology product candidates. Prior
to Medarex, he served as president and chief executive officer of Chiron
Corporation from 2003 until its acquisition by Novartis in 2006. Mr.
Pien held an 11-year tenure at GlaxoSmithKline and its predecessor,
SmithKline Beecham, most recently serving as president of
GlaxoSmithKline International. Earlier in his career, Mr. Pien held
roles of increasing responsibility at Abbott Laboratories and at Merck &
"SAGE's targeted and differentiated approach to drug identification is
compelling and has shown promise in developing treatments for critical
and orphan CNS diseases," said Mr. Pien. "I am privileged to join the
very talented SAGE team as the company works to discover, develop and
deliver important new medicines to patients in need."
About SAGE Therapeutics
SAGE Therapeutics is a neuroscience-focused company developing medicines
to treat life-threatening, rare CNS disorders. SAGE's lead program,
SAGE-547, is in clinical development for super-refractory status
epilepticus (SRSE) and is the first of many compounds the company is
developing in its portfolio of potential seizure medicines. SAGE's
robust chemistry platform has generated multiple new compounds that
target the GABAA and NMDA receptors, which have demonstrated
preclinical activity. SAGE Therapeutics is a private company launched in
2010 by an experienced team of R&D leaders, CNS experts and investors.
For more information, please visit www.sagerx.com.
[ Back To TMCnet.com's Homepage ]